Skip to main content
logo
Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
9.82
+0.29 (3.04%)
At close: Oct 30, 2025, 4:00 PM EDT
9.95
+0.13 (1.32%)
After-hours: Oct 30, 2025, 7:28 PM EDT

Company Description

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.

The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.

Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc.
Rezolute logo
CountryUnited States
Founded2010
IndustryBiotechnology
SectorHealthcare
Employees71
CEONevan Elam

Contact Details

Address:
275 Shoreline Drive, Suite 500
Redwood City, California 94065
United States
Phone650 206 4507
Websiterezolutebio.com

Stock Details

Ticker SymbolRZLT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001509261
CUSIP Number76200L309
ISIN NumberUS76200L3096
Employer ID27-3440894
SIC Code2834

Key Executives

NamePosition
Nevan ElamChief Executive Officer
Daron EvansChief Financial Officer

Latest SEC Filings

DateTypeTitle
Oct 21, 20258-KCurrent Report
Oct 17, 2025SCHEDULE 13GFiling
Oct 7, 2025DEF 14AOther definitive proxy statements
Sep 22, 2025SCHEDULE 13GFiling
Sep 17, 202510-KAnnual Report
Sep 17, 20258-KCurrent Report
Sep 2, 20258-KCurrent Report
Aug 20, 20258-KCurrent Report
Aug 8, 2025EFFECTNotice of Effectiveness
Aug 6, 2025SCHEDULE 13G/AFiling
View All SEC Filings